The Biotech Brief brings you clear, concise updates on the most impactful developments in biotechnology, precision medicine, and life science innovation. Produced by The HEII (Hub for Empowering Impactful Initiatives), this podcast breaks down clinical trial wins, regulatory shifts, and emerging therapeutic strategies in a format designed for busy scientists, entrepreneurs, investors, and changemakers. If you’re new to following the industry, this podcast is also for you. Stay informed. Stay inspired. Stay briefed.
All content for The Biotech Brief is the property of The HEII and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
The Biotech Brief brings you clear, concise updates on the most impactful developments in biotechnology, precision medicine, and life science innovation. Produced by The HEII (Hub for Empowering Impactful Initiatives), this podcast breaks down clinical trial wins, regulatory shifts, and emerging therapeutic strategies in a format designed for busy scientists, entrepreneurs, investors, and changemakers. If you’re new to following the industry, this podcast is also for you. Stay informed. Stay inspired. Stay briefed.
Ocular Therapeutix is rebranding and repositioning. This episode of The Biotech Brief breaks down their plans for competing in the Wet AMD space, the company’s brand pivot to be more retina focused, and why this branding shift is more strategic than cosmetic.
The Biotech Brief
The Biotech Brief brings you clear, concise updates on the most impactful developments in biotechnology, precision medicine, and life science innovation. Produced by The HEII (Hub for Empowering Impactful Initiatives), this podcast breaks down clinical trial wins, regulatory shifts, and emerging therapeutic strategies in a format designed for busy scientists, entrepreneurs, investors, and changemakers. If you’re new to following the industry, this podcast is also for you. Stay informed. Stay inspired. Stay briefed.
